Onkologie. 2020:14(4):178-181 | DOI: 10.36290/xon.2020.062

Options of precision medicine in clinical oncological practice

Stanislav John
Ústav lékařské biologie a genetiky, LF UK v Hradci Králové
Klinika onkologie a radioterapie, FN Hradec Králové

The complexity of oncological treatment has resulted in an effort towards high individualization and rational use. Indeed, advanced molecular analyses of tumour and non-tumour tissues are being used more increasingly and should help us achieve this individualization. Particularly in terms of newly introduced medicinal products in the form of targeted (biological) therapy and immunotherapy, some types of molecular test are even required. Sometimes, we can perform testing above and beyond our normal obligations and bring additional variants in the treatment algorithm of a cancer patient. So, what are the options of molecular analyses in clinical oncological practice in the Czech Republic

Keywords: precision oncology, targeted therapy, predictive testing, sequencing.

Published: September 23, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
John S. Options of precision medicine in clinical oncological practice. Onkologie. 2020;14(4):178-181. doi: 10.36290/xon.2020.062.
Download citation

References

  1. Slamon DJ, Leyland-Jones B, Shak S., Fuchs H, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001; 344(11): 783-792. Go to original source... Go to PubMed...
  2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010; 376(9742): 687-697. Go to original source... Go to PubMed...
  3. Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics, 2019; 13: 33-51. Go to original source... Go to PubMed...
  4. Fountzilas G, Dafni U, Bobos M, Kotoula V, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer, 2013; 13: 163. Go to original source... Go to PubMed...
  5. Mills JN, Rutkovsky AC, Giordano A. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol, 2018; 41. 59-65. Go to original source... Go to PubMed...
  6. Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol, 2019; 11: 1758835919856494. Go to original source... Go to PubMed...
  7. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer, 2009; 45(10): 1890-1896. Go to original source... Go to PubMed...
  8. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol, J2019; 16(6): 361-375. Go to original source... Go to PubMed...
  9. Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol, 2018; 29(5): 1108-1119. Go to original source... Go to PubMed...
  10. Oppelt P J, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol, J2017; 8(3): 466-473. Go to original source... Go to PubMed...
  11. Zhu H, Wei M, Xu J, Hua J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer, 2020; 19(1): 49. Go to original source... Go to PubMed...
  12. Cocco E, Scaltriti M, Drilon A.NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol, 2018; 15(12): 731-747. Go to original source... Go to PubMed...
  13. Pham TV, Boichard A, Goodman A, Riviere P, et al. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol Oncol, 2020; 14(8): 1680-1694. Go to original source... Go to PubMed...
  14. Cardoso F, Van't Veer LJ, Bogaerts J, Slaets L, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med, 2016; 375(8): 717-729. Go to original source... Go to PubMed...
  15. Sparano JA, Gray RJ, Makower DF, Pritchard KI, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med, 2018; 379(2): 111-121. Go to original source... Go to PubMed...
  16. Soukupova J, Zemankova P, Lhotova K, Janatova M, et al. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One, 2018; 13(4): e0195761. Go to original source... Go to PubMed...
  17. Laduca H, Stuenkel AJ, Dolinsky JS, Keiles S, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med, 2014; 16(11): 830-837. Go to original source... Go to PubMed...
  18. Dhir M, Choudry HA, Holtzman MP, Pingpank JF, et al. Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies. Cancer Med, 2017; 6(1): 195-206. Go to original source... Go to PubMed...
  19. Cheng DT, Prasad M, Chekaluk Y, Benayed R, et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med Genomics, 2017; 10(1): 33. Go to original source... Go to PubMed...
  20. Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, et al. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res, 2018; 24(12). 2719-2731. Go to original source... Go to PubMed...
  21. Modrá kniha České onkologické společnosti. Edtion ed.: Masarykův onkologický ústav, Žlutý kopec 7, 656 53 Brno, www.mou.cz, 2020. ISBN 978-80-86793-49-8.
  22. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010; 376(9742): 687-697. Go to original source... Go to PubMed...
  23. Cardoso F, Van't veer LJ, Bogaerts J, Slaets L, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med, 2016; 375(8): 717-729. Go to original source... Go to PubMed...
  24. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol, 2018; 15(12): 731-747. Go to original source... Go to PubMed...
  25. Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics, 2019; 13: 33-51. Go to original source... Go to PubMed...
  26. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer, 2009; 45(10): 1890-1896. Go to original source... Go to PubMed...
  27. Dhir M, Choudry HA, Holtzman MP, Pingpank JF, et al. Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies. Cancer Med, 2017; 6(1): 195-206. Go to original source... Go to PubMed...
  28. Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, et al. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol, 2019; 11: 1758835919856494. Go to original source... Go to PubMed...
  29. Fountzilas G, Dafni U, Bobos M, Kotoula V, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer, 2013; 13: 163. Go to original source... Go to PubMed...
  30. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol, 2019; 16(6): 361-375. Go to original source... Go to PubMed...
  31. Cheng DT, Prasad M, Chekaluk Y, Benayed R, et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med Genomics, 2017; 10(1): 33. Go to original source... Go to PubMed...
  32. Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, et al. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res, 2018; 24(12): 2719-2731. Go to original source... Go to PubMed...
  33. Laduca H, StuenkeL AJ, Dolinsky JS, Keiles S, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med, 2014; 16(11): 830-837. Go to original source... Go to PubMed...
  34. Mills JN, Rutkovsky AC, Giordano A. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol, 2018; 41: 59-65. Go to original source... Go to PubMed...
  35. Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol, 2017; 8(3): 466-473. Go to original source... Go to PubMed...
  36. Pham TV, Boichard A, Goodman A, Riviere P, et al. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. Mol Oncol, 2020; 14(8): 1680-1694. Go to original source... Go to PubMed...
  37. Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol, 2018; 29(5): 1108-1119. Go to original source... Go to PubMed...
  38. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001; 344(11): 783-792. Go to original source... Go to PubMed...
  39. Soukupova J, Zemankova P, Lhotova K, Janatova M, et al. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One, 2018; 13(4): e0195761. Go to original source... Go to PubMed...
  40. Sparano JA, Gray RJ, Makower DF, Pritchard KI, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med, 2018; 379(2): 111-121. Go to original source... Go to PubMed...
  41. Zhu H, Wei M, Xu J, Hua J, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer, 2020; 19(1): 49. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.